The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with Arbaclofen
Open accessAbstract
Pharmacological activation of the GABA B receptor with arbaclofen in a mouse model of fragile X syndrome corrects neuronal defects associated with the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of the GABA B receptor by arbaclofen decreased mRNA translation in the cortex of fragile X mice and corrected the increased spine density 78 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [78]
In the citing paper
“Administration of GABAB agonists, such as baclofen or arbaclofen, corrects exacerbated protein synthesis and multiple phenotypes in Fmr1-KO mice37–39.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“treatment with mGluR antagonists (mavoglurant) and GABAB agonists (arbaclofen), as well as gene reinstatement in Fmr1-KO mice starting in young adult or adult mice, can fully correct most behavioural, physiological, biochemical and neuroanatomical alterations30,32,37.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“No human data are available for SCA1 in the absence of a drug suitable for clinical trials30,32,37.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“For many subtypes of ASD, there is a GABAB deficit and arbaclofen has rescued the behavioral deficits including social deficits in the mouse models of idiopathic ASD [127], deletion of 16p11.2 [128], and FXS [129].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
Self-citationVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Self-citationFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Kaech, S., & Banker, G. A. (2006) · Nature Protocols · doi:10.1038/nprot.2006.356 · Cited by 1,766
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Self-citationAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Self-citationMorphometric study of human cerebral cortex development
Huttenlocher, P. R. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90031-i · Cited by 1,239
Culturing hippocampal neurons.
Tanaka, H. (2002) · Folia Pharmacologica Japonica · doi:10.1254/fpj.119.163 · Cited by 1,141
Kanai, Y., Dohmae, N., & Hirokawa, N. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.022 · Cited by 1,109
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,108
Cited by
Sorted by citations
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Jiang, Y.-H., Yuen, R. K. C., Jin, X., Wang, M., Chen, N., Wu, X., Ju, J., Mei, J., Shi, Y., He, M., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.06.012 · Cited by 474
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491
mTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Self-citationThe GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
Braat, S., & Kooy, R. F. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.042 · Cited by 294
Dysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275
Germline Chd8 haploinsufficiency alters brain development in mouse
Gompers, A. L., Su-Feher, L., Ellegood, J., Copping, N. A., Riyadh, M. A., Stradleigh, T. W., Pride, M. C., Schaffler, M. D., Wade, A. A., Catta-Preta, R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4592 · Cited by 266
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L., Long, S., Ke, X., Fukunaga, K., Lu, Y., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 295
Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
Uzunova, G., Pallanti, S., & Hollander, E. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1085597 · Cited by 257
Targeting the endocannabinoid system in the treatment of fragile X syndrome
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., de la Torre, R., Dierssen, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3127 · Cited by 241
Modeling fragile X syndrome in the Fmr1 knockout mouse
Kazdoba, T. M., Leach, P. T., Silverman, J. L., & Crawley, J. N. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01024 · Cited by 241
Persico, A. M., & Napolioni, V. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.06.012 · Cited by 258
Han, S., Tai, C., Jones, C. J., Scheuer, T., & Catterall, W. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.016 · Cited by 231
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
Progress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
Preclinical research in Rett syndrome: setting the foundation for translational success
Katz, D. M., Berger-Sweeney, J. E., Eubanks, J. H., Justice, M. J., Neul, J. L., Pozzo-Miller, L., Blue, M. E., Christian, D., Crawley, J. N., Giustetto, M., et al. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.011007 · Cited by 206
Silverman, J. L., Pride, M. C., Hayes, J. E., Puhger, K. R., Butler-Struben, H. M., Baker, S., & Crawley, J. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.66 · Cited by 215
Khwaja, O., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., Nelson, C. A., Vogel‐Farley, V. K., DeGregorio, G., Holm, I. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311141111 · Cited by 212
The role of GABAergic signalling in neurodevelopmental disorders
Tang, X., Jaenisch, R., & Sur, M. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00443-x · Cited by 221
The Unstable Repeats—Three Evolving Faces of Neurological Disease
Nelson, D. L., Orr, H. T., & Warren, S. T. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.022 · Cited by 207
Self-citationBjornsson, H. T., Benjamin, J. S., Zhang, L., Weissman, J., Gerber, E. E., Chen, Y.-C., Vaurio, R. G., Potter, M. C., Hansen, K. D., & Dietz, H. C. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009278 · Cited by 196
Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9181-6 · Cited by 183
Self-citationSteadman, P. E., Ellegood, J., Szulc, K. U., Turnbull, D. H., Joyner, A. L., Henkelman, R. M., & Lerch, J. P. (2013) · Autism Research · doi:10.1002/aur.1344 · Cited by 176
Behavioral phenotypes of genetic mouse models of autism
Kazdoba, T. M., Leach, P. T., & Crawley, J. N. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12256 · Cited by 187
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics
Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5003 · Cited by 185
Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-Bowen, K., Bear, M. F., Wang, P. P., & Carpenter, R. L. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.237 · Cited by 168
Self-citationSynaptic proteins and receptors defects in autism spectrum disorders
Chen, J., Yu, S., Fu, Y., & Li, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00276 · Cited by 178
Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 169
Next-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 157
Role of GABAB receptors in learning and memory and neurological disorders
Heaney, C. F., & Kinney, J. W. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.01.007 · Cited by 162
Kim, K. C., Lee, D.-K., Go, H. S., Kim, P., Choi, C. S., Kim, J., Jeon, S. J., Song, M., & Shin, C. Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8535-2 · Cited by 138
A framework for the investigation of rare genetic disorders in neuropsychiatry
Sanders, S., Şahin, M., Hostyk, J. A., Thurm, A. E., Jacquemont, S., Avillach, P., Douard, E. A., Martin, C. L., Modi, M. E., Moreno-De-Luca, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0581-5 · Cited by 131
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Erickson, C. A., Veenstra-VanderWeele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., Scahill, L. D., Cherubini, M., Zarevics, P., Walton-Bowen, K. L., et al. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1963-z · Cited by 128
Self-citationTang, X., Drotar, J., Li, K., Clairmont, C. D., Brumm, A. S., Sullins, A., Wu, H., Liu, X. S., Wang, J., Gray, N. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau0164 · Cited by 120
Korb, E., Herre, M., Zucker-Scharff, I., Gresack, J. E., Allis, C. D., & Darnell, R. B. (2017) · Cell · doi:10.1016/j.cell.2017.07.033 · Cited by 122
Of Men and Mice: Modeling the Fragile X Syndrome
Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133
Sidorov, M. S., Deck, G. M., Dolatshahi, M., Thibert, R. L., Bird, L. M., Chu, C. J., & Philpot, B. D. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9195-8 · Cited by 116
The FMRP regulon: from targets to disease convergence
Fernández, E., Rajan, N., & Bagni, C. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00191 · Cited by 117
Drug discovery for autism spectrum disorder: challenges and opportunities
Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P., & Santarelli, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4102 · Cited by 108
Tchaconas, A., & ADESMAN, A. R. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835c2b70 · Cited by 116
Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome
Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome
Thomson, S. R., Seo, S. S., Barnes, S. A., Louros, S. R., Muscas, M., Dando, O., Kirby, C., Wyllie, D. J. A., Hardingham, G. E., Kind, P. C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.013 · Cited by 100
Self-citationChannelopathies in fragile X syndrome
Deng, P., & Klyachko, V. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00445-9 · Cited by 112
Fragile X syndrome: From protein function to therapy
Bagni, C., & Oostra, B. A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36241 · Cited by 110
Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V. B., Lahiri, D. K., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3022-z · Cited by 105
Wilkinson, C. L., & Nelson, C. A. (2021) · Molecular Autism · doi:10.1186/s13229-021-00425-x · Cited by 101
Delayed myelination in a mouse model of fragile X syndrome
Pacey, L. K. K., Xuan, I. C. Y., Guan, S. A., Sussman, D., Henkelman, R. M., Chen, Y., Thomsen, C., & Hampson, D. R. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt246 · Cited by 105
Prenatal stress and inhibitory neuron systems: implications for neuropsychiatric disorders
Fine, R., Zhang, J., & Stevens, H. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.35 · Cited by 96
Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders
Gandhi, T., & Lee, C. C. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592710 · Cited by 97
Stoppel, L. J., Kazdoba, T. M., Schaffler, M. D., Preza, A. R., Heynen, A., Crawley, J. N., & Bear, M. F. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.236 · Cited by 92
Self-citationThe genetic landscape of autism spectrum disorders
Rosti, R. Ö., Sadek, A. A., Vaux, K. K., & Gleeson, J. G. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12278 · Cited by 95
Revitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 92
Doll, C. A., & Broadie, K. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00030 · Cited by 86
Fatemi, S. H., & Folsom, T. D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.010 · Cited by 86
Copf, T. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.008 · Cited by 92
Sinclair, D., Featherstone, R. E., Naschek, M. J., Nam, A. J., Du, A., Wright, S., Pance, K., Melnychenko, O., Weger, R., Akuzawa, S., et al. (2017) · eNeuro · doi:10.1523/eneuro.0380-16.2017 · Cited by 88
Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome
Berry‐Kravis, E. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.001 · Cited by 86
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 89
Lopatina, O. L., Malinovskaya, N. A., Komleva, Y. K., Gorina, Y. V., Shuvaev, A. N., Olovyannikova, R. Y., Belozor, O. S., Belova, O. A., Higashida, H., & Salmina, A. B. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0014 · Cited by 74
Bonnycastle, K., Davenport, E. C., & Cousin, M. A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15035 · Cited by 78
NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome
Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8341-2 · Cited by 78
Asiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78
Self-citationThe virtuous cycle of human genetics and mouse models in drug discovery
Nadeau, J. H., & Auwerx, J. H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0009-9 · Cited by 78
Clinical trials in autism spectrum disorder: evidence, challenges and future directions
Anagnostou, E. A. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000542 · Cited by 74
Uzunova, G., Hollander, E., & Shepherd, J. D. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660046 · Cited by 73
Altered dendritic spine function and integration in a mouse model of fragile X syndrome
Booker, S. A., Domanski, A. P. F., Dando, O., Jackson, A. D., Isaac, J. T. R., Hardingham, G. E., Wyllie, D. J. A., & Kind, P. C. (2019) · Nature Communications · doi:10.1038/s41467-019-11891-6 · Cited by 70
Self-citationNeural circuits regulating prosocial behaviors
Walsh, J. J., Christoffel, D. J., & Malenka, R. C. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01348-8 · Cited by 72
Thabault, M., Turpin, V., Maïsterrena, A., Jaber, M., Egloff, M., & Galvan, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042294 · Cited by 74
Gonzalez, D., Tomasek, M. P., Hays, S. A., Sridhar, V., Ammanuel, S. G., Chang, C.-W., Pawlowski, K. S., Huber, K. M., & Gibson, J. R. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0886-19.2019 · Cited by 64
Deficits in Tactile Learning in a Mouse Model of Fragile X Syndrome
Arnett, M. T., Herman, D. H., & McGee, A. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109116 · Cited by 70
Modulation of the GABAergic pathway for the treatment of fragile X syndrome
Hagerman, R. J., Lozano, R., & Hare, E. B. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42919 · Cited by 70
Stoppel, L. J., Auerbach, B. D., Senter, R. K., Preza, A. R., Lefkowitz, R. J., & Bear, M. F. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.075 · Cited by 67
Self-citationGomis‐González, M., Busquets-García, A., Matute, C., Maldonado, R. J., Mato, S., & Ozaita, A. (2016) · Genes · doi:10.3390/genes7090056 · Cited by 64
Fragile X syndrome and fragile X-associated tremor ataxia syndrome
Hall, D. A., & Berry‐Kravis, E. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00025-7 · Cited by 65
Cortical interneuron dysfunction in epilepsy associated with autism spectrum disorders
Jacob, J. (2015) · Epilepsia · doi:10.1111/epi.13272 · Cited by 65
Qin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv034 · Cited by 62
GABABAgonism Promotes Sleep and Reduces Cataplexy in Murine Narcolepsy
Wurts, S. W., Morairty, S. R., Chen, T.-M., Leung, A. K., Wisor, J. P., Yamanaka, A., & Kilduff, T. S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0080-14.2014 · Cited by 62
Kumari, D., Bhattacharya, A., Nadel, J., Moulton, K., Zeak, N. M., Glicksman, A., Dobkin, C., Brick, D. J., Schwartz, P. H., Smith, C. B., et al. (2014) · Human Mutation · doi:10.1002/humu.22699 · Cited by 61
Revisiting the excitation/inhibition imbalance hypothesis of ASD through a clinical lens
Port, R. G., Oberman, L. M., & Roberts, T. P. L. (2019) · British Journal of Radiology · doi:10.1259/bjr.20180944 · Cited by 68
Brondino, N., Fusar‐Poli, L., Panisi, C., Damiani, S., Barale, F., & Politi, P. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2619-y · Cited by 61
Domanski, A. P. F., Booker, S. A., Wyllie, D. J. A., Isaac, J. T. R., & Kind, P. C. (2019) · Nature Communications · doi:10.1038/s41467-019-12736-y · Cited by 59
Self-citationPort, R. G., Gajewski, C. R., Krizman, E. N., Dow, H. C., Hirano, S., Brodkin, E. S., Carlson, G. C., Robinson, M. B., Roberts, T. P. L., & Siegel, S. J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.013 · Cited by 55
Deficient Sleep in Mouse Models of Fragile X Syndrome
Saré, R. M., Harkless, L. H., Levine, M., Torossian, A., Sheeler, C. A., & Smith, C. B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00280 · Cited by 54
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
TLR3 downregulates expression of schizophrenia gene Disc1 via MYD88 to control neuronal morphology
Chen, C.-Y., Liu, H., & Hsueh, Y. (2016) · EMBO Reports · doi:10.15252/embr.201642586 · Cited by 54
Hyperactivity and lack of social discrimination in the adolescent Fmr1 knockout mouse
Sørensen, E. M., Bertelsen, F., Weikop, P., Skovborg, M. M., Banke, T. G., Drasbek, K. R., & Scheel‐Krüger, J. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000152 · Cited by 59
Mechanisms Underlying Circuit Dysfunction in Neurodevelopmental Disorders
Exposito-Alonso, D., & Rico, B. (2022) · Annual Review of Genetics · doi:10.1146/annurev-genet-072820-023642 · Cited by 49
Fragile X syndrome: From targets to treatments
Wijetunge, L. S., Chattarji, S., Wyllie, D. J. A., & Kind, P. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.028 · Cited by 54
Self-citationKang, J.-Y., Chadchankar, J., Vien, T. N., Mighdoll, M. I., Hyde, T. M., Mather, R. J., Deeb, T. Z., Pangalos, M. N., Brandon, N. J., Dunlop, J., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.772541 · Cited by 50
Novel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 51
From FMRP Function to Potential Therapies for Fragile X Syndrome
Sethna, F., Moon, C., & Wang, H. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1229-3 · Cited by 49
Devitt, N. M., Gallagher, L., & Reilly, R. B. (2015) · Brain Sciences · doi:10.3390/brainsci5020092 · Cited by 84
Lieberman, O. J., Cartocci, V., Pigulevskiy, I., Molinari, M., Carbonell, J., Broseta, M. B., Post, M. R., Sulzer, D., Borgkvist, A., & Santini, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00070 · Cited by 48
Emerging pharmacologic treatment options for fragile X syndrome
Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 44
Metadata
- Authors
- Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., Warren, S. T., Vanderklish, P. W., Kind, P. C., Carpenter, R. L., Bear, M. F., & Healy, A. M.
- Affiliations
- Seaside Therapeutics (United States) (US)
- University of Edinburgh (GB)
- Emory University (US)
- Baylor College of Medicine (US)
- Scripps Research Institute (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Healy, Aileen M.
- Venue
- Science Translational Medicine
- Published
- 2012-09-19
- Volume
- 4
- Issue
- 152
- Pages
- 152ra128-152ra128
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC8826584
- OpenAlex
- W2096270532
- Cited by
- 249
- References
- 102
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 20 · 2021: 21 · 2020: 10 · 2019: 20 · 2018: 8 · 2017: 32 · 2016: 14 · 2015: 25 · 2014: 24 · 2013: 31 · 2012: 11
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 24064, HD020521, R01HD020521, P30HD024064, R37HD020521)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Keywords
- fragile X syndrome, GABAB receptors, baclofen, Fmr1 knockout mice, FMRP, synaptic protein synthesis, dendritic spine morphology, AMPA receptor internalization, mRNA translation, synaptic dysfunction, intellectual disability, autism spectrum disorder, hippocampus
- MeSH terms
- Animals, Baclofen, Behavior, Animal, Disease Models, Animal, Fragile X Syndrome, Hippocampus, Male, Phenotype, Polyribosomes, Seizures, Synapses, Protein Biosynthesis, Receptors, GABA-B, Receptors, AMPA, Mice, Knockout, Protein Transport, Dendritic Spines, Mice, Fragile X Messenger Ribonucleoprotein 1, GABA-B Receptor Agonists, Drinking Water
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
